This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Welcome to InOncology.com

Discover how Boehringer Ingelheim is committed to taking cancer on. Our goal is to transform the lives of patients by developing innovative, first-in-class treatments for lung and gastrointestinal cancers.

LATEST CONGRESSES: OUR ACTIVITIES

Past event
ASCO 2019
ASCO 2019
ASCO 2019 Access materials presented at ASCO; 5 publications and 5 downloads
Past event
WCLC 2019
WCLC 2019
Access materials presented at WCLC; 8 publications and 8 downloads
Past event
ESMO 2019
ESMO 2019
Access materials presented at ESMO; 6 publications and 10 downloads

Physicians´ insights

*This is an investigational compound and has not been approved. Its safety and efficacy have not been established.

**Afatinib is approved in more than 80 markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list, please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

© 2020 Boehringer Ingelheim International GmbH. All rights reserved.

Page last updated: March 2020